PreveCeutical Welcomes Dr. Deepak Sampath, PhD. as Corporate Advisor

Rhea-AI Summary

PreveCeutical Medical has appointed Dr. Deepak Sampath as a corporate advisor effective May 30, 2025. Dr. Sampath brings over 25 years of expertise in molecular and cellular biology, pharmacology, and drug development. His notable achievements include contributing to the FDA approval of venetoclax for CLL/SLL treatment. Currently serving as Senior VP and Head of Research at Ultragenyx, he leads multidisciplinary functions in various scientific fields. Dr. Sampath has published 108 peer-reviewed articles and is named on 21 issued patents and 11 patent applications. His expertise spans protein biologics, nucleic acids, and gene therapies for rare genetic conditions.

Positive

• Appointment of highly experienced advisor with 25+ years in drug development and molecular biology
• Dr. Sampath's track record includes FDA approval of venetoclax for cancer treatment
• Strong intellectual property portfolio with 21 patents and 11 patent applications
• Extensive expertise in multiple therapeutic modalities including gene therapies and protein biologics

Negative

• None.

Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to have appointed Dr. Deepak Sampath as a corporate advisor effective 30 May, 2025.

Stephen Van Deventer, CEO of PreveCeutical, commented:

"We are thrilled to welcome Dr. Deepak Sampath to our Corporate Advisory Board. Deepak's extraordinary career, spanning over 25 years in molecular and cellular biology, pharmacology, and drug development, adds invaluable expertise to PrevCeutical's leadership team. His track record of advancing programs from discovery to clinical development and regulatory approval aligns seamlessly with our mission to deliver transformative therapies for metabolic and genetic disorders. We look forward to his insights as we continue to expand our impact in the life sciences sector."

Dr. Deepak Sampath's Career Highlights:

Dr. Sampath is a distinguished scientist and seasoned executive leader with extensive experience in small molecules, protein biologics, nucleic acids, and gene therapies. His leadership has driven numerous programs from early research and drug discovery into clinical trials and through regulatory approval for commercialization. Most notably, he has made significant contributions to the treatment of oncological diseases, including the FDA approval of venetoclax, a first-in-class BCL-2 selective inhibitor for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). His additional expertise spans the discovery and development of predictive biomarkers, translational research, target identification and validation. Dr. Sampath has also been instrumental in establishing strategic partnerships with academic institutions and industry leaders, ensuring the successful translation of cutting-edge science into therapeutic breakthroughs. Additionally, he has published 108 articles in peer-reviewed journals and is named as an inventor or co-inventor on 21 issued patents and 11 patent applications.

Currently serving as Senior Vice President and Head of Research at Ultragenyx, Dr. Sampath leads multidisciplinary functions with expertise in the fields of Molecular Genetics, Molecular and Cellular Biology, Molecular Therapeutics, Protein Sciences, Bioinformatics and Bioanalytical Research. Additionally, his focus is on translational research of multiple modalities, such as protein biologics, nucleic acids and gene therapies, for the treatment of rare and ultra-rare genetic conditions spanning neurological, metabolic, bone and muscular diseases.

Dr. Sampath remarked on his appointment:

"It is a privilege and honour to join the Corporate Advisory Board of PreveCeutical, a company, I believe, is deeply committed to the discovery and development of novel and transformative therapies to treat a variety of diseases with high unmet medical need. I look forward to supporting and advising the management team in fulfilling their mission and achieving their corporate objectives."

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.

On Behalf of the Board of Directors,

PreveCeutical Medical Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer

For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.

Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedarplus.ca. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254087

FAQ

Who is Dr. Deepak Sampath and what is his role at PreveCeutical (PRVCF)?

Dr. Deepak Sampath was appointed as a corporate advisor at PreveCeutical effective May 30, 2025. He is currently Senior VP and Head of Research at Ultragenyx with over 25 years of experience in molecular biology and drug development.

What are Dr. Sampath's major achievements in drug development?

Dr. Sampath contributed to the FDA approval of venetoclax for chronic lymphocytic leukemia, published 108 peer-reviewed articles, and is named on 21 issued patents and 11 patent applications.

What areas of expertise does Dr. Sampath bring to PreveCeutical (PRVCF)?

Dr. Sampath brings expertise in molecular and cellular biology, pharmacology, drug development, protein biologics, nucleic acids, and gene therapies for rare genetic conditions.

What is Dr. Sampath's current position outside of PreveCeutical?

Dr. Sampath currently serves as Senior Vice President and Head of Research at Ultragenyx, leading multidisciplinary functions in molecular genetics, therapeutics, and bioanalytical research.

How many patents and publications does Dr. Sampath have?

Dr. Sampath has published 108 articles in peer-reviewed journals and is named as an inventor or co-inventor on 21 issued patents and 11 patent applications.